EC Approval of Wegovy Pill Bolsters Novo Nordisk's EU Obesity Franchise but Core Challenges Remain

What happened

Novo Nordisk received European Commission approval for a once-daily oral Wegovy pill for obesity, marking the first GLP-1 tablet for weight management in the EU and expanding its franchise beyond the U.S. market. The approval adds a new growth vector, but the DeepValue master report maintains a WAIT rating, emphasizing that oral Wegovy must prove it can convert prescription growth into durable revenue without further margin erosion. The stock's reaction reflects relief and optimism, yet the underlying issues of US payer rebate escalation, Lilly's competitive pressure, and pipeline credibility remain unresolved. Oral Wegovy's rapid U.S. uptake to over 3 million prescriptions has yet to translate into obesity revenue acceleration, and the EC approval does not alter the need for Q2-Q3 2026 sales evidence. Investors should view this as a positive but not a conclusive catalyst for a higher rating.

Implication

The EC approval adds a new revenue stream and demonstrates regulatory execution, but it does not change the fundamental risk-reward. The stock still trades at approximately 12x earnings, reflecting skepticism that oral Wegovy's volume can offset price and mix deterioration. Until Q2-Q3 obesity sales show revenue conversion and REIMAGINE 4 data de-risk the pipeline, the risk of further downside from competitive pressure and pricing resets remains elevated. A more attractive entry point remains near $44, where downside from weak quarters would be better compensated.

Thesis delta

The EC approval slightly bolsters the bull case by expanding Wegovy's addressable market beyond the US, but it does not alter the central thesis that Novo must prove oral volume translates into revenue without destroying price. The master report's bear and base scenarios already included oral Wegovy scaling; this news increases the probability of the base case but does not eliminate the key risks from Lilly's competition and US pricing pressure. As such, the WAIT rating and attractive entry of $44 remain appropriate.